Furthermore, encapsulating VA in LNP-DP1 can further increase its therapeutic effect and safety in HCC treatment, which guarantees future research into investigating the novel combination of VA plus PD-1 inhibitors. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.